China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the launch of its innovative biotechnology patent platform, WuXiUI. Developed based on the ultra-enhanced flow plus cell culture process, this platform is designed to be suitable for mainstream cell lines and various molecular types, marking a significant advancement in bioprocessing.
WuXiUI: Enhancing Production and Quality
The WuXiUI platform is engineered to enhance the production and quality of various product types expressed in different CHO cell lines and other mammalian cell lines. This innovative approach is estimated to reduce the production cost of the raw solution in a disposable bioreactor by 60-80% compared to traditional flow plus cell culture processes, offering substantial economic benefits.
Scalability and Environmental Impact
WuXiUI is designed for easy application and scalability in existing production facilities, eliminating the need for additional main equipment or complex operations. It allows for the continued use of conventional downstream production processes for protein purification. Moreover, WuXiUI significantly reduces medium consumption and waste liquid volume, contributing to more environmentally friendly production practices.-Fineline Info & Tech
